Home > Gastroenterology > AK104 plus chemotherapy promising first-line option for gastric cancer

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By
Dr Jiafu Ji, Beijing Cancer Hospital, China
Conference
ASCO GI 2022
Trial
Phase 1/2, AK104-201
The combination therapy of the PD-1/CTLA-4 bispecific antibody AK104 plus chemotherapy showed promising activity and a manageable safety profile in patients with advanced gastric or gastroesophageal junction (GEJ) cancer [1]. The results of the current AK104-201 phase 1b/2 study drove the design of a phase 3 study investigating this combination therapy. “Synergy between immune checkpoint inhibitors and chemotherapy in gastric or GEJ cancer has been demonstrated in 2 studies,” Dr Jiafu Ji (Beijing Cancer Hospital, China) said [2,3]. “In addition, we have learned that anti-PD-1 plus anti-CTLA-4 co-therapy outperforms anti-PD-1 alone, but at the cost of higher toxicity.” The current phase 1b/2 AK104-201 study (NCT04380805) assessed the efficacy and safety of AK104, a PD-1/CTLA-4 bispecific antibody, in combination with XELOX or modified XELOX as first-line ther...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on